[Solved] Pharm week 6 Reply to Peer 1

Assignment Prompt & Instructions

**Week 6 Discussion: Patient With Polydipsia and Weight Gain**
**Nonpharmacologic Treatments Recommended to FM**
Given FM's diagnosis of new-onset type 2 diabetes mellitus (T2DM), lifestyle modifications are critical. The following nonpharmacologic strategies are recommended:
– **Medical nutrition therapy (MNT):** A referral to a registered dietitian is recommended to develop a meal plan that supports weight loss and glycemic control. FM should be educated on carbohydrate counting and choosing low-glycemic index foods (American Diabetes Association [ADA], 2024).
– **Physical activity:** FM should engage in at least 150 minutes per week of moderate-intensity aerobic activity and strength training twice weekly, as tolerated (ADA, 2024).
– **Behavioral counseling:** Counseling or behavioral therapy is advised to address emotional eating and mental health, especially in light of FM’s reported loneliness and depression during the pandemic.
– **Self-monitoring:** FM should be educated on how to monitor his blood glucose at home, given his elevated A1c and random glucose levels.
**Pharmacologic Treatments Recommended or Avoided**
Due to FM's significant hyperglycemia (random glucose of 358 mg/dL and A1c of 11.4%), pharmacologic therapy is indicated.
– **Recommended:**
– **Metformin** is the first-line pharmacologic agent unless contraindicated. It enhances insulin sensitivity and has a favorable weight profile (ADA, 2024).
– **GLP-1 receptor agonists** (e.g., semaglutide) or **SGLT2 inhibitors** (e.g., empagliflozin) may be added for further glycemic control, weight reduction, and cardiovascular benefit. These classes are advantageous for patients with obesity and elevated cardiovascular risk (Davies et al., 2022).
– **Avoided:**
– **Sulfonylureas** and **insulin** may promote weight gain and hypoglycemia and may not be ideal as initial treatments unless FM is experiencing severe hyperglycemia symptoms.
– **Thiazide diuretics** (e.g., hydrochlorothiazide) can worsen glycemic control. Switching to a more metabolically favorable antihypertensive should be considered (ADA, 2024).
**Additional Laboratory Tests Recommended**
– **Fasting lipid panel:** To assess cardiovascular risk and guide statin therapy.
– **Serum creatinine and estimated glomerular filtration rate (eGFR):** To evaluate renal function before initiating metformin or SGLT2 inhibitors.
– **Liver function tests:** Baseline testing is necessary prior to initiating some antidiabetic agents.
– **Urine albumin-to-creatinine ratio (UACR):** To screen for diabetic nephropathy.
– **Thyroid-stimulating hormone (TSH):** To rule out thyroid dysfunction, which can impact weight and glycemic control.
**References**
American Diabetes Association. (2024). _Standards of care in diabetes—2024_. _Diabetes Care, 47_(Supplement 1), S1–S200. [https://doi.org/10.2337/dc24-S001](https://doi.org/10.2337/dc24-S001)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., … & Wexler, D. J. (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the ADA and the European Association for the Study of Diabetes (EASD). _Diabetes Care, 45_(11), 2753–2786. [https://doi.org/10.2337/dci22-0034](https://doi.org/10.2337/dci22-0034)